Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-0726-2022Class II

HeartWare Ventricular Assist Device (HVAD) System

HeartWare, Inc. / initiated 2022-01-27 / Open, Classified / root cause: labeling and UDI

Heartware, Inc. began a recall of HeartWare Ventricular Assist Device (HVAD) System on . FDA classified it as Class II and gives the reason as "Updated cleaning instructions are being provided for the Controller AC Adapter, DC Adapter, and Battery to provide clarity to avoid cleaning the power source connector pins, as this could remove the lubricant that is...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as labeling and UDI.

Recall record

Recall number
Z-0726-2022
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
HeartWare, Inc.
Product
HeartWare Ventricular Assist Device (HVAD) System
Product code
DSQ Ventricular (Assist) Bypass
Reason for recall
Updated cleaning instructions are being provided for the Controller AC Adapter, DC Adapter, and Battery to provide clarity to avoid cleaning the power source connector pins, as this could remove the lubricant that is applied to the pins as a mitigation for power switching.
Root cause tag
labeling and UDI
FDA root cause
Labeling design
Action
Starting 27-Jan-2022 and ending 02-FEB-2022, Medtronic initiated an Urgent Medical Device Notice to global customers to inform them of the intent to update the cleaning instructions for power source connector pins on the HVAD" System Monitor AC Adapter, DC Adapter, and Batteries. The communication provided customers the updated instructions, the complaints received as well as the potential hazards of cleaning the power source connector pins. In addition to the Urgent Medical Device Notice a patient template was provided to facilitate the VAD Coordinators in notifying their patients. In the United States the notice was delivered to VAD Coordinators via UPS 2-day delivery. Consignees will be asked to confirm receipt of the letter and that they have acknowledge the actions taken for those nonimplanted, affected product. In addition, a courtesy copy was sent to shared care clinics for those affected patients. Outside the United States the notice will be delivered to consignees through a locally approved method. Consignees will be asked to confirm receipt of the letter and that they have taken the recommended action. Confirmation of the communication will be received by locally approved methods.
Quantity in commerce
197,889 units
Distribution
Distribution throughout the United States. OUS distribution in Argentina, Armenia, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Kazakhstan, Korea (South), Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Malaysia, Mauritius, Netherlands, New Zealand, North Macedonia, Norway, Pakistan, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Arab Emirates, United Kingdom, and Vietnam.
Product codes and lots
All lots/serials for the following product model numbers: 1440, 1400, 1401, 1401AU, 1401BR, 1401CA, 1401CH, 1401DE, 1401GB, 1401IL, 1401IN, 1401IT, 1401JP, 1401US, 1403US, 1407AR, 1407AU, 1407BR, 1407CA, 1407CA-CLIN, 1407CH, 1407DE, 1407GB, 1407IL, 1407IN, 1407IT, 1407JP, 1407KR, 1425AU, 1425CA, 1425DE, 1425GB, 1425IL, 1425IT, 1425US, 1430AR, 1430AU, 1430CA, 1430CH, 1430DE, 1430GB, 1430IL, 1430IN, 1430IT, 1430JP, 1430US, 1440, 1650, 1650, 1650CA-CLIN, 1650DE

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-0726-2022
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-0726-2022Class IIOngoingVoluntary: Firm initiated